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Pluripotent stem cells have long-term proliferative capacity and an unusual mode of cell-cycle regulation and
can divide independently of extrinsic mitogenic signals. The last few years has seen evidence emerge that
links cell-cycle regulation to the maintenance and establishment of pluripotency. Myc transcription factors
appear to be central to this regulation. This review addresses these links and discusses how cell-cycle
controls and Myc impact on the maintenance and establishment of pluripotency.Connections between theMyc family of transcription factors and
cell-cycle control have been of constant interest to biologists for
over 25 years. This relationship is particularly evident in the study
of tumor biology, where deregulated Myc activity is known to
play a central role in aberrant cell proliferation and immortaliza-
tion. More recently, there has been considerable interest in
defining the role of Myc in the biology of a broad range of stem
cells. In embryonic stem cells (ESCs), for example, Myc is
required for maintenance of the pluripotent state (Cartwright
et al., 2005) and for establishment of the stem cell state by
way of reprogramming (Takahashi and Yamanaka, 2006).
Recent evidence suggests that Myc’s role in pluripotency is con-
nected with its ability to regulate the cell-cycle machinery. In this
review, we discuss these recent advances and how an under-
standing of Myc and cell-cycle control will lead to a more
complete understanding of pluripotency and reprogramming.
Pluripotent Cells in Early Embryos: Cell-Cycle Control
and Rapid Cell Division
Uncommitted, pluripotent cells in vertebrate pregastrula
embryos undergo extraordinarily rapid rounds of cell division.
This trend is associated with cell cycles consisting of alternating
rounds of DNA replication (S phase) and chromosome segrega-
tion-cell separation (M phase) without intervening gap phases,
such as in cleavage-stage Xenopus embryos (Murray and
Kirschner, 1989). Since all the maternal determinants for devel-
opment are deposited in the egg prior to fertilization, zygotic
transcription is not required until the midblastula transition
when uncommitted cells become specified. The nature of this
cell-cycle structure thus promotes the rapid amplification in
cell number necessary for early embryonic development. Varia-
tions of this general theme also apply during earlyDrosophila and
zebrafish development to enable rapid expansion in cell number
just prior to gastrulation (Edgar and Lehner, 1996; Yarden and
Geiger, 1996).
In rodents, peri-implantation development is dependent on zy-
gotic programs, and so cell-cycle progression is driven by de
novo RNA and protein synthesis. Expansion of the rodent
embryo immediately prior to gastrulation is dependent on a rapid
burst of pluripotent cell proliferation, with average generation
times estimated to be 4.5–8.0 hr (Snow, 1977; Lawson et al.,1991). These cells exhibit an unusual cell-cycle structure, char-
acterized by a short G1 gap phase and a high proportion of S
phase cells (65%). Since G1 is the period of the cell cycle
when cell growth primarily occurs, this pattern has often been
used to rationalize why pluripotent cells are small in size. As
pluripotent cells become specified into one of the three germ
layers, the cell cycle typically restructures so that the length of
G1 is extended, leading to increased division times and a general
increase in cell volume (Lawson et al., 1991). These observations
raise the question as to whether there is some mechanistic rela-
tionship between pluripotency, cell-cycle structure, and cell size
control.
A Cell-Cycle Structure Synonymous with Pluripotency
Cell-cycle regulation of pluripotent cells has been extensively
characterized in ESCs, first with mouse (see White and Dalton,
2005) and more recently with rhesus monkey (Fluckiger et al.,
2006) and human (Neganova et al., 2009; Zhang et al., 2009)
lines. In general, pluripotent ESCs retain the cell-cycle dynamics
of their counterparts in the peri-implantation stage embryo
(Snow, 1977; Lawson et al., 1991; Stead et al., 2002). Murine
ESCs divide rapidly with generation times of8–10 hr and spend
65% of their time in S phase and 15% of their time in G1.
Upon differentiation, the cell cycle is remodeled such that the
percentage of cells in G1 increases to over 40% and generation
times increase to >16 hr (Stead et al., 2002; White et al., 2005).
These features of cell-cycle control appear to be conserved in
rhesus monkey ESCs (Fluckiger et al., 2006), murine epiblast
stem cells (EpiSCs; Tesar et al., 2007; Brons et al., 2007), human
and murine induced pluripotent stem cells (iPSCs), and hESCs
(Figure 1; Ohtsuka and Dalton, 2008; Dalton, 2009). Although
hESCs and human iPSCs exhibit a cell-cycle structure similar
to the other pluripotent cell types discussed so far, their cell divi-
sion cycle times are significantly slower (32–38 hr; Ohtsuka and
Dalton, 2008; Dalton, 2009), indicating that rapid division is not
a necessary property of pluripotent cells. This conclusion is sup-
ported by other observations showing that slowing the mESC
cell cycle with chemical inhibitors has no measurable impact
on self-renewal or differentiation potential (Stead et al., 2002).
We are unaware of any accurate estimates of generation times
for human pluripotent cells in early development, and so it isCell Stem Cell 5, August 7, 2009 ª2009 Elsevier Inc. 141
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variations or are due to technical issues associated with culture
conditions. It is generally thought, based on crude population
doubling measurements, that hESC proliferation accelerates
when cells become aneuploid, presumably due to the acquisition
of selective growth advantages (Brimble et al., 2004; Draper
et al., 2004; Mitalipova et al., 2005). There are caveats to this
hypothesis, however, since differences in apoptotic rates under
different conditions can also impact on population expansion.
Nevertheless, care must be taken because aneuploidy can
have a number of unanticipated effects on the biology of plurip-
otent cells. Although iPSCs are considered to be fully reprog-
rammed, partially reprogrammed cells (PRCs) can also be
obtained using established methods for generating iPSCs (Mik-
kelsen et al., 2008; Silva et al., 2008; Sridharan et al., 2009).
These cells self-renew but do not expressmarkers characteristic
of pluripotent cells and exhibit a cell-cycle profile intermediate
between pluripotent cells and adult fibroblasts (Figure 1).
In total, rapid cell division is not a prerequisite for the self-re-
newing, pluripotent state. Instead, we suggest that mechanisms
underpinning cell-cycle structure are more central to the mech-
anisms governing the stem cell state. The following discussion
will tackle what the relationship between cell cycle, self-renewal,
and pluripotency may be.
The Significance of a Cell Cycle Lacking Full Gap Phases
Pluripotent cells of the epiblast, embryonal carcinoma cells
(ECCs), embryonic germ cells (EGCs), ESCs, EpiSCs, early prim-
itive ectoderm-like cells (EPL cells), and iPSCs all exhibit cell
cycles consisting of a truncated G1 phase and a high proportion
Figure 1. Cell-Cycle Structure of Human and Murine Pluripotent
Cells and Fibroblasts
Typical cell-cycle profiles from a range of pluripotent cell types (mESC, hESC,
miPSC, hiPSC, and mEpiSC) and primary fibroblasts are depicted. Pluripotent
cells spend a high proportion of time in S phase and a low proportion of time in
G1 (Savatier et al., 1996; Stead et al., 2002; Fluckiger et al., 2006; Ohtsuka and
Dalton, 2008; Dalton, 2009; Neganova et al., 2009; Zhang et al., 2009). MEFs
and human IMR90 fibroblasts show a lower percentage of cells in S phase and
an increased proportion in G1 relative to pluripotent cells. hPRCs display
a cell-cycle structure intermediate between differentiated fibroblasts and
pluripotent cells. The positions of G1 cells (2n DNA content), S phase cells,
and G2/M cells (4n DNA content) are indicated. The y axis represents the rela-
tive number of cells, and the x axis represents the DNA content of cells,
a readout for cell-cycle position.142 Cell Stem Cell 5, August 7, 2009 ª2009 Elsevier Inc.of cells in S phase (see Figure 1; Savatier et al., 1996; Stead et al.,
2002; White et al., 2005). The possible relationship between
cell-cycle structure, self-renewal, and differentiation was first
addressed over 20 years ago by Christine Mummery in ECCs.
These early studies in ECCs indicate that cells preferentially
initiate differentiation from the G1 phase (Mummery et al.,
1987; Jonk et al., 1992). The underlying principle behind these
studies was that a short G1 limits the ‘‘window of opportunity’’
during which a cell can be responsive to differentiation cues.
For example, if differentiation is dependent on the threshold of
an induction signal, or if there is a cumulative effect over time,
it makes sense that shortening G1would serve to limit the poten-
tial for differentiation. This model predicts that an extended G1
phase would make cells more responsive to differentiation
signals and that cell-cycle remodeling would be a prerequisite
for efficient differentiation. An extended period of time in S phase
may further shield cells from extrinsic differentiation cues, by
reducing the proportion of time in G1. This general idea is sup-
ported by studies in hESCs demonstrating that inhibition of G1
progression compromises pluripotency (Filipczyk et al., 2007).
Devoting a high proportion of time to S phase could also facil-
itate the maintenance of chromatin in a euchromatic state. The
highly euchromatic genome of pluripotent cells (Herrera et al.,
1996) is likely to facilitate rapid activation (or repression) of genes
in response to positional specification cues. This model can be
thought of as ‘‘differentiation competency’’ and, as argued
above, could be regulated by cell-cycle control mechanisms.
On a similar note, it has been proposed that displacement of
transcription factors from condensing chromatin during mitosis
may create an opportunity to reset developmentally important
transcriptional programs during the following G1 phase (Egli
et al., 2008). The length of G1would therefore serve as a potential
window in which this conversion could occur. If chromatin in
pluripotent cells exists in an open configuration, repressing
and activating blocks of genes could require a longer remodeling
period than that available during the short G1 phase of pluripo-
tent cells. This and other scenarios presented by us require
that the length of G1 increases coincidentally with differentiation.
Technically, this hypothesis is very difficult to test and has not, as
yet, been addressed in cells outside of ECCs.
Rodent and primate pluripotent cells are generally thought to
undergo symmetric divisions, where two self-renewing daughter
cells are generated following eachmitosis (Zwaka and Thomson,
2005). It is unclear if iPSCs divide by an asymmetric or symmetric
mode, but for the purposes of this discussion, we assume they
also generate two identical daughter cells at mitosis. One issue
that receives little attention when pluripotent cells are discussed
is their relatively small size (Takahashi and Yamanaka, 2006; Te-
sar et al., 2007) and how cell volume generally increases during
differentiation. Based on other studies, in which G1 has been
shown to be a major period of cell growth (Saucedo and Edgar,
2002; Jorgensen and Tyers, 2004; Baserga, 2007), it is likely that
increased cell size is associated with cell-cycle restructuring.
More broadly, this issue raises questions about how cells reset
their size as they transition between different states. These ques-
tions underscore the need to characterize in greater detail how
cell-cycle and cell volume controls are coordinated in pluripotent
cells. This point is important from a stem cell perspective but also
from a developmental perspective, in that size and cell-cycle
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(Snow, 1977; Lawson et al., 1991).
Regulation of Proliferation in Self-Renewing,
Pluripotent Cells
To appreciate the remarkable features of pluripotent cell-cycle
control, it is useful to be reminded of the established principles
underpinning growth control in mammalian cells of somatic
origin. The established view involves the strict requirement for
mitogenic signaling in order for a cell to proceed through G1
and into S phase. In the absence of active mitogenic signaling,
cells exit the cycle at some point in G1 and enter a quiescent
phase (Go) but retain the capacity to re-enter the cell cycle
upon further mitogenic stimulation. This proliferative ‘‘gateway,’’
known as the restriction (R) point, must be passed through in
every cell cycle and mechanistically constitutes a nexus
between mitogenic signaling pathways and the cell-cycle
machinery (Pardee, 1974). Once past this control point, cells
become committed to completing the cell cycle and require no
further mitogenic signaling. Well-known exceptions to this prin-
ciple are tumor cells that acquire mutations in one or more of
the regulatory genes required for R point control. Consequently,
cells become mitogen independent and cycle in the absence of
growth factors (Sherr, 1996).
We will begin by considering mESCs, since they are the most
studied of available pluripotent populations. In contrast to a
typical somatic cell, signaling through the mitogenic Ras/Mek/
Erk pathway does not enhance cell-cycle progression of mESCs
but instead promotes their differentiation (Burdon et al., 1999).
This change in cell fate also coincides with a deceleration in
progression through the cell cycle (White et al., 2005), which
appears to be an indirect result of the Ras pathway signal.
Consistent with this effect, growth factor withdrawal from
mESC cultures has no impact on proliferation rates but eventu-
ally contributes to apoptosis (Schratt et al., 2001). Mitogen-inde-
pendent cell-cycle control in mESCs is therefore reminiscent of
the behavior of tumor cells and reiterates the well-established
connection between immortalization and factor-independent
growth control (see Ohtsuka and Dalton, 2008). A caveat to
Figure 2. The Relationships between Pluripotency Regulators, Cell
Cycle, and Cell Size Control
The core transcriptional network (Oct4, Nanog, and Sox2), together with Myc,
regulates key aspects of pluripotent cell biology, including the cell cycle and
cell size. This is achieved in conjunction with the PI3K-mTOR signaling
pathway and through the regulation of miRNAs.this discussion is that autocrine factors produced by pluripotent
cells may be required for their proliferation, and thus pluripotent
populations may not be truly growth factor independent.
At an early stage during differentiation, mESCs become de-
pendent on extrinsic factors and lose their tumorigenic capacity
(Chambers and Smith, 2004; Blum and Benvenisty, 2008),
implying some link between tumorigenicity and mitogen-inde-
pendent proliferation in pluripotent cells (see Ying et al., 2008).
The tumorigenic properties of pluripotent cells can be rational-
ized by the activity of several genes, which in other contexts
are involved in tumor progression. The proto-oncogene c-myc,
for example, plays key roles in pluripotent cell establishment
and maintenance (Cartwright et al., 2005). Moreover, an ESC-
specific form of Ras (ERas) that drives PI3K is required for robust
teratoma formation in transplantation assays and contributes to
the rapid cell division ofmESCs (Takahashi et al., 2003). A role for
PI3K signaling in rapid mESC cell division was implied initially
from experiments in which inactivation of PTEN accelerated
progression through G1 (Sun et al., 1999). Although PI3K is firmly
established as a major regulator of ESC self-renewal (see Paling
et al., 2004; Takahashi et al., 2005; Watanabe et al., 2006;
McLean et al., 2007), how it accelerates G1 progression in plurip-
otent cells has not been defined. Clues to answer this question
come from studies showing that PI3K/mTOR co-ordinates cell-
cycle progression by coupling it to cell growth control (Alvarez
et al., 2003; Fingar et al., 2004; Figure 2). In contrast to pluripo-
tent cells of rodent origin, hESCs lack a functional ERas gene
(Kameda and Thomson, 2005), perhaps explaining differences
in proliferation rates between rodent and human cell lines. The
mitogenic requirements for hESCs are now only starting to be
understood, and it is unclear if they are totally independent of
extrinsic factors. One potential factor that could impact on
hESC proliferation, Fgf2, exhibits no mitogenic activity but rather
serves to sustain pluripotency (Filipczyk et al., 2007). However,
other extrinsic factors that drive PI3K activity, such as Igf and
insulin, could perform promitogenic functions.
When the cell cycle of rodent pluripotent cells is examined,
several additional regulatory themes appear to be shared with
tumor cells. Such analysis indicates that mESCs lack an intact
R point because the retinoblastoma protein (pRb) is held in a
constitutively hyperphosphorylated state (Savatier et al., 1994),
E2F transcription factors are free of pRb family members, and
E2F-dependent transcription displays no periodicity throughout
the cell cycle (Stead et al., 2002). These observations can be ac-
counted for by unusually high levels of cyclin-dependent kinase
2 (Cdk2)-cyclin E/A; by Cdk6-cyclin D3 activity; and by the
absence of Cdk inhibitory molecules such as p21Cip1, p27Kip1,
and INK family members such as p16Ink4a (Stead et al., 2002;
Faast et al., 2004). With the exception of Cdk1-cyclin B, all other
Cdk activities are constitutively active throughout the cell cycle,
which explains why tumor suppressor proteins such as pRb are
held in an inactive state and how pluripotent cells have only a
brief G1 phase. Many features of mESC cell-cycle control and
cell growth can in fact be recapitulated in mouse embryonic
fibroblasts (MEFs) following genetic inactivation of the three
pRb family members (pRb, p107, p130). For example, Rb triple
knockout (TKO) MEFs progress through G1 at an accelerated
rate and exhibit a cell cycle profile similar to that of mESCs
(Sage et al., 2000). Up to 65% of Rb-TKO MEFS are in S phase,Cell Stem Cell 5, August 7, 2009 ª2009 Elsevier Inc. 143
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Moreover, Rb-TKO cells are resistant to contact inhibition, prolif-
erate independently of growth factors, fail to undergo replicative
senescence, and show a 40%–50% decrease in cell volume
(Sage et al., 2000; Dannenberg et al., 2000). The decrease in
cell size likely reflects their accelerated progression through
G1. All of these characteristics are hallmarks of ESCs and were
discussed earlier in this review. Perhaps most intriguing,
however, is the observation that Rb-TKO cells exhibit a reduced
efficiency for differentiation into multiple lineages (Dannenberg
et al., 2000). This defect suggests that active pRb family
members are required for differentiation, perhaps by controlling
chromatin remodeling (Macaluso et al., 2006) or by helping to
establish a new mode of G1 cell-cycle control. The establish-
ment of cell-cycle-regulated Cdk activity during the early steps
of differentiation could provide a mechanism to explain how
pRb family members become activated, thereby enabling cells
to differentiate efficiently. Inactivation of the Rb family by preco-
cious Cdk activity (Stead et al., 2002; Faast et al., 2004) could
therefore be a focal point for regulation of the cell cycle and
self-renewal, just as it is in transformed cells.
Rhesus monkey ESCs are similar to mESCs, as they also
display constitutive cyclin-Cdk activities, proliferate by a
mitogen-independent mechanism, and cycle rapidly with a short
G1 phase (Fluckiger et al., 2006). In contrast, hESCs cycle slowly
(32–38 hr) but retain a cell cycle with a high proportion of S
phase and low percentage of cells in G1 (Neganova et al.,
2009). There is also some evidence indicating that Cdk activities
display modest periodicity (2- to 3-fold fluctuations) during the
cell cycle in hESCs—a departure from the absence of periodicity
in murine and rhesus ESCs (Neganova et al., 2009). This pattern
suggests that cyclical Cdk activitymaybe associatedwith slower
rounds of division and that constitutive activity is related to more
rapid division. Following this theme, the cell-cycle structure char-
acteristic of pluripotent cells therefore seems to be independent
of the pattern of Cdk activity. Instead, rates of division seem to
correlate more with its constitutive or cyclic pattern of regulation
in the cell cycle. Differences in themagnitude of overall Cdk activ-
ities could also be a contributing factor, since murine pluripotent
cells divide extremely rapidly and have unprecedentedly high
global Cdk activity (Stead et al., 2002; Faast et al., 2004).
If Cdk regulation in human pluripotent cells is more reminis-
cent of that in untransformed somatic cells, it is unlikely that
constitutive Cdk activity per se is a requirement for self-renewal
and pluripotency. Instead, we are left to contemplate other
factors that may underpin self-renewal and pluripotency, such
as cell-cycle structure.
A direct relationship between core regulators of the pluripotent
stateand thecell cyclehas recentlybeendescribed (seeFigure2).
First, involving Oct4 and Sox2, which regulate miR-302, a regu-
lator of cyclin D1, Rb, E2F1, and p130 (Card et al., 2008). A
second report, by Zhang and coworkers (Zhang et al., 2009),
implicates Nanog in the regulation of CDK6 and CDC25A, key
components of the G1 cell-cycle machinery. The overarching
implication of these studies is that an intimate relationship exists
between mechanisms of pluripotency and cell-cycle regulation.
The role of cell-cycle regulation in the establishment of pluripo-
tency will be discussed later in the context of reprogramming
and iPSC derivation (see below).144 Cell Stem Cell 5, August 7, 2009 ª2009 Elsevier Inc.Cell-Cycle Remodeling and Differentiation:
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As pluripotency is lost during differentiation, cells undergo awide
range of biological changes. These include remodeling of the cell
cycle, adjustment of cell size controls, loss of tumorigenic
capacity, and acquisition of contact-inhibited and mitogen-
dependent growth. Growth factor dependence has not been
evaluated in human pluripotent cells, but murine ESCs transition
from being factor independent to factor dependent as they
differentiate (Schratt et al., 2001; Ying et al., 2008). This change
is consistent with the imposition of R point control in G1 during
early cell-fate commitment (Stead et al., 2002; Faast et al.,
2004; White et al., 2005).
Since we know most about mESCs, it is easiest to first
comment on the above-mentioned aspects of differentiation in
the context of rodent cells. One thing that immediately stands
out when G1 controls are evaluated is the lack of any apparent
growth restraints on the cell-cycle machinery. When mESCs
differentiate, Cdk activities become cell cycle regulated and
decrease in magnitude (White et al., 2005). How cells transition
from one mode of Cdk regulation to the other is unclear, but
this decline in Cdk activity can be accounted for by the upregu-
lation of Cdk inhibitory molecules such as p21Cip1, p27Kip1, and
members of the INK family. The INK family shows specific
patterns of upregulation depending on which lineage is specified
(Zindy et al., 1997; Faast et al., 2004), indicating that lineage-
specific mechanisms of cell-cycle regulation operate during
the early stages of cell-fate commitment. Upregulation of inhib-
itory proteins is accompanied by a general decline in cyclin
levels, which themselves become cell cycle dependent due to
changes in their regulation at the transcriptional and posttran-
scriptional levels. All of these observations are likely to be inter-
connected, but it is unclear what triggers this series of events.
The key regulatory event that transitions cells from being
tumor-like to a cell with intact growth controls and cell-cycle-
regulated activities is still not understood.
Perhaps the most relevant points of regulation that can
account for dramatic growth control changes are those associ-
ated with establishment of the R point machinery. Specifically,
the introduction of cell-cycle-regulated pRb phosphorylation
and E2F-dependent transcription are central to the onset of a
functioning R point. Imposition of G1 growth controls seems to
explain the switch from factor independency to factor depen-
dency, establishment of contact inhibition, and even changes
in cell size controls. It is tempting then, to suggest that these
changes also underpin mechanistic aspects of cell-fate commit-
ment, but it is unclear if these events are related to ‘‘cause or
effect.’’ We anticipate that rhesus ESCs will undergo similar
changes in cell-cycle regulation in differentiation to that
described for murine cells.
Human pluripotent cells represent a different scenario, as at
least some G1 controls appear to be operative (Becker et al.,
2006; Ghule et al., 2007; Neganova et al., 2009). Nevertheless,
hESCs must remodel their cell cycle as they differentiate, so as
to increase the proportion of time in G1 and to allow for changes
in size control. How this transition occurs is unclear but according
to earlier work is likely to be underpinned by changes in Cdk2
activity (Stead et al., 2002). Neganova et al. (2009) recently tested
this idea in hESCs and provide evidence indicating that elevated
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state. These findings are consistent with the earlier report of Fili-
pczyk et al. (2007) showing that normal progression throughG1 is
required to maintain pluripotency. These are perhaps the most
compelling argumentsmade yet to invoke a role for the cell-cycle
machinery in maintenance of pluripotency.
Cell-Cycle Control, Immortalization, and Size Control:
Do All Roads Lead to Myc?
When thinkingabout potential regulators of stemcell self-renewal
and pluripotent cell-cycle control, one candidate immediately
comes to mind: the Myc transcription factor family (c-, N-, and
L-myc). The members of the Myc family of basic helix-loop-helix
transcription factors, in particular c- andN-Myc, havewell-estab-
lished roles in control of cell-cycle progression, cell immortaliza-
tion, and tumor progression (Meyer and Penn, 2008). Moreover,
Myc has established roles in blocking cell differentiation and in
maintaining progenitor populations in vivo (Knoepfler et al.,
2002; Kenney et al., 2004; Satoh et al., 2004; Okubo et al.,
2005). Myc has many roles in normal proliferative control and
cell-fate determination, but when its activity is deregulated, it
becomes oncogenic. It should be noted that in some contexts,
Myc canpromote progenitor differentiation, rather thanmaintain-
ing the undifferentiated state (Wilson et al., 2004; Watt et al.,
2008). TheMyc familymembers therefore exhibit context-depen-
dent effects on cell fate. The exact functions of Myc transcription
factors have been difficult to decipher, probably because of their
context-dependent functions and because they regulate
hundreds, or possibly thousands, of genes in vivo (Fernandez
et al., 2003). It has been speculated that in contrast to a typical
transcription factor, which regulates a limited number of genes
through cis-acting regulatory elements, Myc functions as an
epigenetic ‘‘licensing’’ factor. In this model, Myc binds to regula-
tory regions of many genes that together are part of a transcrip-
tional program required for cell-fate determination and identity
(see Guccione et al., 2006). Consistent with this hypothesis,
Myc has been implicated in the regulation of a large network of
genes in conjunction with Cnot3 and Trim28, two factors recently
identified as being critical for pluripotency (Hu et al., 2009). Regu-
lation of this network appears to be independent of Oct4 and
Sox2, suggesting that multiple transcriptional control networks
may operate in pluripotent cells. The complexity of Myc-depen-
dent gene regulation is made greater by the fact that Myc acti-
vates and represses target genes through E box-dependent
and -independent mechanisms (Ryan and Birnie, 1996). We will
now review the evidence that establishes Myc as being critical
for maintenance and establishment of the pluripotent state.
Unlike other transcription factors, such as Oct4, Nanog, and
Sox2, which have key roles in maintaining the self-renewing
pluripotent state, there is no direct evidence linking Myc to the
development of pluripotent cells in the peri-implantation stage
embryo. The absence of an early developmental phenotype in
either c- or N-myc knockout mice can be explained by the over-
lapping expression of these functionally redundant family
members (Malynn et al., 2000). Simultaneous inactivation of
multiple Myc family members has so far not been reported in
early development and will be required before this lingering
question can be formally answered. There are precedents,
however, where c- and N-myc perform redundant roles in stemcell proliferation and survival—a recently described example
being in hematopoietic stem cells (Laurenti et al., 2008).
Since a self-renewing stem cell must divide indefinitely and
avoid replicative senescence, it is not surprising that factors
shown to be important for cell transformation, such as Myc,
are also involved in self-renewal. The first evidence for this rela-
tionship came from Cartwright et al. (2005), who demonstrated
that ectopic Myc expression could relieve the dependency of
mESCs for LIF. More recently, ectopic Myc expression has
been shown to promote a metastable pluripotent state (Hanna
et al., 2009). A role for Myc in mESC self-renewal is consistent
with its dramatic downregulation during the early stages of differ-
entiation (Cartwright et al., 2005).
There are several lines of evidence to support the idea that
elevatedMyc activity accounts for many of the cell-cycle proper-
ties of pluripotent cells. First, elevated c-myc accelerates pro-
gression through G1 by positively regulating cyclin-Cdk activity
(Amati et al., 1998). This regulation occurs at multiple levels, in-
cluding transcriptional and posttranscriptional control involving
the upregulation of cyclins and suppression of Cdk inhibitors
such as p21Cip1 and p27Kip1. Second, cell-cycle changes that
occur during the early stages of pluripotent cell differentiation
coincide with the collapse of Myc levels (Cartwright et al.,
2005;White et al., 2005). In addition to previous reports in cancer
cell models, the regulatory subunit of telomerase (TERT) has
been confirmed as an in vivo target of Myc in mESCs (Kim
et al., 2008). These observations begin to placeMyc at the center
of a regulatory network that links self-renewal mechanisms to the
cell-cycle machinery in pluripotent cells (see Figure 2).
How Myc contributes to the establishment and maintenance
of pluripotent cells has been the subject of several recent reports
focusing on the identification of in vivo target genes (Kim et al.,
2008; Kidder et al., 2008). Cell-cycle genes clearly emerge as
being regulatory targets, consistent with Myc being the center-
piece for cell-cycle regulation in pluripotent cells. These studies
still leavemany questions unanswered as themechanism behind
Myc’s regulation of specific target genes remains undefined. The
key to solving this puzzle may lie with the role played by ESC-
specific microRNAs (miRNAs), which have recently been shown
to coordinate the expression of cell-cycle control molecules
such as p21Cip1 and cyclin D2 (Wang et al., 2008; Lee et al.,
2008). These reports establish that when miRNA function is
lost, p21 and cyclin D2 become elevated, resulting in loss of
pluripotency. Judson and coworkers have recently suggested
that maintaining the expression of ESC-specific miRNAs may
in fact be regulated directly by Myc (Judson et al., 2009; dis-
cussed below). Maintaining the balance of cell-cycle-regulatory
molecules therefore appears to be critical for the pluripotent
state. Myc appears to be central to this tightly interconnected
mechanism.
The Cell Cycle and Myc: Part of the Reprogramming
Mechanism Required for iPSC Formation?
As discussed previously, pluripotent cells have a signature
cell-cycle structure, where cells spend a proportionally short
period of time in G1 and a proportionally long period of time in
S phase (see Figure 1). Cell types typically used to generate
iPSCs exhibit a significantly different cell-cycle structure, and
as reprogramming proceeds, a pluripotent cell-cycle structureCell Stem Cell 5, August 7, 2009 ª2009 Elsevier Inc. 145
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Regulatory Controls Intersect with Different
Stages of Reprogramming
Cells subject to reprogramming cues undergo
a three-step process as they transition toward
iPSCs. The initial step involves Myc, which causes
global changes in genes expression, including
repression of differentiation genes, without induc-
tion of pluripotency genes (see Sridharan et al.,
2009; Zhao and Daley, 2008; Maherali et al.,
2008; Judson et al., 2009; Silva et al., 2008;Mikkel-
sen et al., 2008). Other reprogramming factors,
possibly in combination with Myc (Huangfu et al.,
2008), then drive the formation of PRCs and then
fully reprogrammed iPSCs. Roles for Myc have
also been defined in the maintenance of iPSCs
and other pluripotent cell types, some of which
are directly related to cell-cycle control (Cartwright
et al., 2005; Wang et al., 2008; Judson et al., 2009;
Hanna et al., 2009). Possible points at which Myc
could be involved, but for which there are no solid
data, are indicated by broken arrows. For
example, it is likely that cells in the process of
being reprogrammed need to be constantly kept
cycling by Myc.and mechanism of control is established. This cell-cycle struc-
ture does not appear to be imposed, however, in PRCs, and
so the characteristic cell-cycle structure is established during
the later stages of reprogramming (Figure 1). It is unknown if
re-establishment of pluripotent cell-cycle control mechanisms
is ‘‘cause or effect’’ with regards to reprogramming, but we
would argue, based on the evidence to be presented, that it is
at least integrally involved.
The arguments used previously to invoke a role for cell-cycle
control in maintenance of the pluripotent state also apply to
the maintenance of iPSCs, and so this topic will not be covered
again. Instead, we will discuss potential mechanisms where the
cell cycle and its control by Myc could impact on the establish-
ment of the pluripotent state, such as in iPSC generation (see
Knoepfler, 2008). In the context of cell-cycle control, the most
obvious role for Myc during reprogramming may be a require-
ment for the parental cells to be cycling when exposed to reprog-
ramming factors. This scenario has been posed byMaherali et al.
(2008) to explain why some cell types reprogrammore efficiently
and more rapidly than others. Keratinocytes for example, repro-
gram more efficiently than fibroblasts and express higher levels
of Myc. Differences in Myc expression levels in different cell
types could also explain why exogenous Myc is dispensable
for iPSC formation in some cell types. In this scenario, endoge-
nous Myc activity could be sufficient to work in conjunction
with other exogenous factors. Neural progenitors, for example,
do not require exogenous Myc for reprogramming, because
they express high endogenous levels (Han et al., 2008). Overall,
it appears clear that at least some Myc expression is required
during reprogramming, but when and how Myc participates
remains open to question. One proposed argument, as
mentioned above, holds that Myc simply maintains cells in a
proliferative state in which they respond better to the other re-
programming factors. In this scenario, Myc and the cell-cycle
machinery would also halt the onset of replicative senescence.
Zhao and Daley (2008) have pointed out that a precondition for
reprogramming may be the inactivation of senescence factors
such as pRb and p53—perhaps by Myc-dependent regulation146 Cell Stem Cell 5, August 7, 2009 ª2009 Elsevier Inc.of Cdk. It has not escaped our attention that this collection of
changes amounts to the establishment of a transformed-like
state, in which tumor suppressors are inactivated and onco-
genes activated to generate a quasi-immortal, self-renewing
cell. A mechanistic survey of four reprogramming factors
(c-myc, Klf4, Oct4, and Sox2) found that c-myc is critical for
the early stages of reprogramming (Sridharan et al., 2009). This
study suggests that, in addition to maintaining cells in a prolifer-
ative state, Myc performs a role in silencing genes associated
with differentiation by broadlymodifying the epigenetic signature
of a cell by enhancing global histone acetylation (see Knoepfler
et al., 2006). This effect can be thought of as a ‘‘priming’’ function
that enables cells to become receptive to other factors required
for the latter stages of reprogramming. This scenario is consis-
tent with a model in which Myc participates in the regulation of
large blocks of genes involved in cell-fate determination, as
described earlier. In addition to having a role during the initial
stages of reprogramming, Myc may also function at multiple
stages of iPSC formation (Figure 3), since it is likely that cells
need to be in a proliferative state throughout the reprogramming
process. Multistage effects of Myc are also suggested by the
early work of Cartwright et al. (2005), who initially demonstrated
roles for c-myc in pluripotency maintenance and also more
recently from Hanna and coworkers (Hanna et al., 2009), who
showed that c-myc promotes a metastable pluripotent state.
Finally, c-myc controls the expression of ESC-specific miRNAs
that can be used as a substitute for Myc in reprogramming of
fibroblasts, in conjunction with Oct4, Sox2, and Klf4 (Judson
et al., 2009). In total, these data strongly argue that Myc is a crit-
ical reprogramming factor that serves multiple functions at
different stages of iPSC formation/maintenance. These roles
are likely to involve cell-cycle-related and cell-cycle-indepen-
dent functions (Figure 3).
Closing Comments
This review has discussed the broad relationship between
mechanisms of pluripotency, cell-cycle control, and reprogram-
ming. Figures 2 and 3 depict a summary of the interrelationships
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Reviewbetween these pathways and howMyc transcription factors may
participate in these processes. Myc family members are well-es-
tablished regulators of G1 progression and can impact on cell
size by driving cells into S phase by mechanisms impacting on
Cdk activity. Myc is not the only component of the transcription
factor network that plays a role in cell-cycle control of pluripotent
cells. Sox2 and Oct4 control the cell cycle through miRNAs, and
Nanog regulates G1 progression at the transcriptional level.
Together, these observations provide clear relationships bet-
ween the fundamentals of pluripotency and the cell division
cycle. While the model portrayed here highlights the key compo-
nents of cell cycle and size control in pluripotent cells, the details
of how everything fits together need to be clarified in greater
detail. We are left with many unanswered questions, but recent
progress, over the last 3 years in particular, points to the likeli-
hood of a more complete understanding of their interrelation-
ships in the near future. In total, the connections between cell
cycle, pluripotency, and reprogramming are somewhat unex-
pected findings that solidify a unique mode of cell-cycle regula-
tion as an integral component of the pluripotent state.
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